Viral suppression off ART using dual bNAb therapy
Now recruiting in 7 UK sites
The RIO study is looking at whether a new type of treatment can keep viral load undetectable without antiretroviral therapy (ART). This will involve asking all participants to stop ART for a short time.
The study will measure how long viral load stays undetectable without ART. It will also look at what happens to the HIV virus and immune system in blood samples. When virus becomes detectable in a blood test (viral rebound) participants will be asked to re-start their ART.
RIO is jointly coordinated by Imperial College London (Sponsor), The University of Oxford and The Rockefeller University. The study is funded by the Bill & Melinda Gates Foundation.
There are 9 UK centres participating in RIO: Royal Free Hospital, St Mary’s Hospital, Mortimer Market Centre, Royal Sussex County Hospital Brighton, Chelsea and Westminster Hospital, Royal London Hospital, Guy’s Hospital, Manchester University NHS Foundation Trust and NHS Lothian.
41 participants have so far been recruited to the study.
We are pleased to report that the RIO trial protocol has now been published in the peer-reviewed journal Trials.
Please find the manuscript here.
For more information about RIO please visit the RIO trial website.